PUBLIC RESEARCH DOSSIER
REPL · Nasdaq瑞普利缪恩
Manufacturing · Biological Products, (No Diagnostic Substances)完成交易日收盘US$20.65+5.95%行情日期 2026-11-03 · 非实时
公开资料页汇总瑞普利缪恩（REPL）的已发布行情、估值、风险、财务摘要与同业对比。行情截至2026-11-03，非实时；缺失值不按零处理。
股价走势
复权收盘价（美元）
2025-10-31 — 2026-11-03253 个交易日样本
REPLUS$20.65
查看图表数据
| 日期 | REPL |
|---|---|
| 2025-10-31 | 9.73 |
| 2025-11-03 | 9.31 |
| 2025-11-04 | 8.97 |
| 2025-11-05 | 8.58 |
| 2025-11-06 | 8.5 |
| 2025-11-07 | 8.31 |
| 2025-11-10 | 8.71 |
| 2025-11-11 | 9.13 |
| 2025-11-12 | 9.04 |
| 2025-11-13 | 8.98 |
| 2025-11-14 | 8.99 |
| 2025-11-17 | 8.77 |
| 2025-11-18 | 8.74 |
| 2025-11-19 | 8.99 |
| 2025-11-20 | 9.01 |
| 2025-11-21 | 9.2 |
| 2025-11-24 | 9.39 |
| 2025-11-25 | 9.53 |
| 2025-11-26 | 10.06 |
| 2025-11-28 | 10 |
| 2025-12-01 | 9.71 |
| 2025-12-02 | 10 |
| 2025-12-03 | 10.32 |
| 2025-12-04 | 10.53 |
| 2025-12-05 | 10.61 |
| 2025-12-08 | 10.73 |
| 2025-12-09 | 10.3 |
| 2025-12-10 | 9.82 |
| 2025-12-11 | 9.87 |
| 2025-12-12 | 10.18 |
| 2025-12-15 | 9.95 |
| 2025-12-16 | 9.61 |
| 2025-12-17 | 9.66 |
| 2025-12-18 | 9.69 |
| 2025-12-19 | 9.88 |
| 2025-12-22 | 9.93 |
| 2025-12-23 | 9.72 |
| 2025-12-24 | 10.09 |
| 2025-12-26 | 9.96 |
| 2025-12-29 | 9.76 |
| 2025-12-30 | 9.82 |
| 2025-12-31 | 9.72 |
| 2026-01-02 | 8.9 |
| 2026-01-05 | 8.42 |
| 2026-01-06 | 8.45 |
| 2026-01-07 | 8.92 |
| 2026-01-08 | 8.23 |
| 2026-01-09 | 8.03 |
| 2026-01-12 | 8.11 |
| 2026-01-13 | 8.04 |
| 2026-01-14 | 7.71 |
| 2026-01-15 | 7.3 |
| 2026-01-16 | 7.04 |
| 2026-01-20 | 7.01 |
| 2026-01-21 | 7.26 |
| 2026-01-22 | 7.9 |
| 2026-01-23 | 7.71 |
| 2026-01-26 | 7.56 |
| 2026-01-27 | 7.53 |
| 2026-01-28 | 7.36 |
| 2026-01-29 | 7.39 |
| 2026-01-30 | 7.03 |
| 2026-02-02 | 6.98 |
| 2026-02-03 | 7.38 |
| 2026-02-04 | 7 |
| 2026-02-05 | 6.93 |
| 2026-02-06 | 7.75 |
| 2026-02-09 | 7.78 |
| 2026-02-10 | 7.8 |
| 2026-02-11 | 7.76 |
| 2026-02-12 | 7.98 |
| 2026-02-13 | 7.97 |
| 2026-02-17 | 7.26 |
| 2026-02-18 | 8.04 |
| 2026-02-19 | 8.55 |
| 2026-02-20 | 8.64 |
| 2026-02-23 | 8.39 |
| 2026-02-24 | 8.36 |
| 2026-02-25 | 8.2 |
| 2026-02-26 | 7.69 |
| 2026-02-27 | 7.65 |
| 2026-03-02 | 7.16 |
| 2026-03-03 | 7.17 |
| 2026-03-04 | 7.25 |
| 2026-03-05 | 7.04 |
| 2026-03-06 | 8.07 |
| 2026-03-09 | 8.63 |
| 2026-03-10 | 8.23 |
| 2026-03-11 | 7.9 |
| 2026-03-12 | 7.58 |
| 2026-03-13 | 7.14 |
| 2026-03-16 | 7.36 |
| 2026-03-17 | 7 |
| 2026-03-18 | 6.76 |
| 2026-03-19 | 6.89 |
| 2026-03-20 | 6.98 |
| 2026-03-23 | 6.98 |
| 2026-03-24 | 6.97 |
| 2026-03-25 | 7.56 |
| 2026-03-26 | 7.54 |
| 2026-03-27 | 7.22 |
| 2026-03-30 | 7.2 |
| 2026-03-31 | 7.65 |
| 2026-04-01 | 7.61 |
| 2026-04-02 | 8.41 |
| 2026-04-06 | 8.54 |
| 2026-04-07 | 7.8 |
| 2026-04-08 | 5.89 |
| 2026-04-09 | 5.91 |
| 2026-04-10 | 4.76 |
| 2026-04-13 | 1.7 |
| 2026-04-14 | 1.95 |
| 2026-04-15 | 2.28 |
| 2026-04-16 | 2.19 |
| 2026-04-17 | 2.17 |
| 2026-04-20 | 2.07 |
| 2026-04-21 | 1.86 |
| 2026-04-22 | 2.27 |
| 2026-04-23 | 2.85 |
| 2026-04-24 | 2.42 |
| 2026-04-27 | 2.68 |
| 2026-04-28 | 2.57 |
| 2026-04-29 | 2.38 |
| 2026-04-30 | 2.57 |
| 2026-05-01 | 2.5 |
| 2026-05-04 | 3.03 |
| 2026-05-05 | 2.87 |
| 2026-05-06 | 3.44 |
| 2026-05-07 | 3.34 |
| 2026-05-08 | 4.07 |
| 2026-05-11 | 3.74 |
| 2026-05-12 | 4.09 |
| 2026-05-13 | 5.3 |
| 2026-05-14 | 4.93 |
| 2026-05-15 | 5.22 |
| 2026-05-18 | 5.01 |
| 2026-05-19 | 4.7 |
| 2026-05-20 | 5.16 |
| 2026-05-21 | 5.22 |
| 2026-05-22 | 4.91 |
| 2026-05-26 | 4.6 |
| 2026-05-27 | 4.7 |
| 2026-05-28 | 4.68 |
| 2026-05-29 | 8.69 |
| 2026-06-01 | 9 |
| 2026-06-02 | 8.87 |
| 2026-06-03 | 9.98 |
| 2026-06-04 | 9.87 |
| 2026-06-05 | 9.47 |
| 2026-06-08 | 8.97 |
| 2026-06-09 | 9.24 |
| 2026-06-10 | 8.47 |
| 2026-06-11 | 8.62 |
| 2026-06-12 | 8.88 |
| 2026-06-15 | 8.96 |
| 2026-06-16 | 8.78 |
| 2026-06-17 | 10 |
| 2026-06-18 | 10.19 |
| 2026-06-22 | 11.18 |
| 2026-06-23 | 11.42 |
| 2026-06-24 | 11.27 |
| 2026-06-25 | 11.13 |
| 2026-06-26 | 11.63 |
| 2026-06-29 | 11.2 |
| 2026-06-30 | 11.07 |
| 2026-07-01 | 11.22 |
| 2026-07-02 | 11.58 |
| 2026-07-06 | 11.47 |
| 2026-07-07 | 11.51 |
| 2026-07-08 | 11.12 |
| 2026-07-09 | 11.11 |
| 2026-07-10 | 10.99 |
| 2026-07-13 | 9.94 |
| 2026-07-14 | 9.87 |
| 2026-07-15 | 9.68 |
| 2026-07-16 | 9.52 |
| 2026-07-17 | 10.23 |
| 2026-07-20 | 10.51 |
| 2026-07-21 | 11 |
| 2026-07-22 | 10.75 |
| 2026-07-23 | 10.46 |
| 2026-07-24 | 9.7 |
| 2026-07-27 | 8.63 |
| 2026-07-28 | 5.35 |
| 2026-07-29 | 5.41 |
| 2026-07-30 | 5.41 |
| 2026-07-31 | 11.2 |
| 2026-08-03 | 11.91 |
| 2026-08-04 | 11.92 |
| 2026-08-05 | 11.83 |
| 2026-08-06 | 12.86 |
| 2026-08-07 | 12.06 |
| 2026-08-10 | 13.67 |
| 2026-08-11 | 13.65 |
| 2026-08-12 | 15.24 |
| 2026-08-13 | 15.19 |
| 2026-08-14 | 14.97 |
| 2026-08-17 | 14.63 |
| 2026-08-18 | 15.58 |
| 2026-08-19 | 14.81 |
| 2026-08-20 | 14.05 |
| 2026-08-21 | 14.77 |
| 2026-08-24 | 14.71 |
| 2026-08-25 | 15.8 |
| 2026-08-26 | 15.88 |
| 2026-08-27 | 15.6 |
| 2026-08-28 | 15.5 |
| 2026-08-31 | 15.3 |
| 2026-09-01 | 15.67 |
| 2026-09-02 | 15.98 |
| 2026-09-03 | 15.29 |
| 2026-09-04 | 15.04 |
| 2026-09-08 | 14.77 |
| 2026-09-09 | 14.45 |
| 2026-09-10 | 13.24 |
| 2026-09-11 | 12.92 |
| 2026-09-14 | 13.11 |
| 2026-09-15 | 13.03 |
| 2026-09-16 | 12.96 |
| 2026-09-17 | 12.87 |
| 2026-09-18 | 13.07 |
| 2026-09-21 | 12.87 |
| 2026-09-22 | 13.47 |
| 2026-09-23 | 12.96 |
| 2026-09-24 | 12.6 |
| 2026-09-25 | 12.36 |
| 2026-09-28 | 12.56 |
| 2026-09-29 | 13 |
| 2026-09-30 | 13.24 |
| 2026-10-01 | 13.45 |
| 2026-10-02 | 13.07 |
| 2026-10-05 | 13.15 |
| 2026-10-06 | 13.25 |
| 2026-10-07 | 13.2 |
| 2026-10-08 | 13.04 |
| 2026-10-09 | 13.42 |
| 2026-10-12 | 13.07 |
| 2026-10-13 | 12.11 |
| 2026-10-14 | 11.39 |
| 2026-10-15 | 11.75 |
| 2026-10-16 | 10.86 |
| 2026-10-19 | 11.05 |
| 2026-10-20 | 11.42 |
| 2026-10-21 | 11.72 |
| 2026-10-22 | 11.99 |
| 2026-10-23 | 11.46 |
| 2026-10-26 | 12.47 |
| 2026-10-27 | 13.05 |
| 2026-10-28 | 16.06 |
| 2026-10-29 | 17.39 |
| 2026-10-30 | 17.61 |
| 2026-11-02 | 19.49 |
| 2026-11-03 | 20.65 |
1、3、6、12个月分别按21、63、126、252个交易日取区间；缺失日期不从区间外补齐。
使用已有每日复权收盘样本，非实时行情；图中价格可能与未复权收盘报价不同。
01 · MARKET FRAME
行情、估值与风险
基于已完成交易日和已发布财务资料
区间涨跌幅
区间涨跌幅使用复权收盘价；估值和风险指标缺失时显示为—，不按零处理。
02 · FINANCIAL TRACE
财务摘要
公开页仅显示最近3个已校验报告期
年度财务走势
百万美元 · 年度报告期
所选指标暂无已校验的年度资料，缺失值不按零处理。
| 指标 | 2026-08-11 | 2026-06-30 | 2026-03-31 | 2025-08-04 | 2025-06-30 | 2025-03-31 | 2024-08-05 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|
| 营收 | — | — | — | — | — | — | — | — | — |
| 净利润 | — | — | -313.9 | — | — | -247.3 | — | — | -215.8 |
| 自由现金流 | — | — | -284.6 | — | — | -198.9 | — | — | -191.1 |
| 股份数 | 94.2 | — | — | 78.1 | — | — | 68.3 | — | — |
| 债务 | — | — | — | — | — | — | — | — | — |
| 总资产 | — | 252.4 | — | — | 469.5 | — | — | 535 | — |
金额及股份数均以百万为单位。缺失或待核验数据不按零处理。
03 · PEER SET
同业对比
同一细分行业中市值最接近的公司
| 公司 | 市值 | 近250日涨跌幅 | 市盈率 | 距52周高点 | 波动率 |
|---|---|---|---|---|---|
| VIR维尔生物技术 | US$1.9B | +113.7% | — | -6% | +64.1% |
| COAGHemab Therapeutics Holdings, Inc. | US$2B | — | — | — | — |
| VCELVericel Corp | US$2.1B | +13.4% | 86.9× | -14.9% | +41.2% |
| MAZEMaze治疗 | US$1.8B | -0.5% | — | -37.8% | +67.4% |
同业由已覆盖公司的行业分类和市值接近度确定，仅用于横向研究；缺失数据不按零处理。